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Clinical outcomeAbstract Introduction: The antiplatelet drug aspirin is considered as a cornerstone in medical
treatment of patients with CV or cerebrovascular diseases. Despite its use, a signiﬁcant number
of patients had recurrent adverse ischemic events. Inter-individual variability of platelet aggregation
in response to aspirin may be an explanation for some of these events. Multiple trials have linked
aspirin resistance to these adverse events.
Objectives: The aim of this study was to estimate the prevalence of aspirin resistance among
patients with coronary artery disease (CAD) in Egypt and evaluate its impact on clinical outcome.
Methods: A total of 50 patients with documented history of CAD were included; they were on
aspirin 150 mg/day for more than seven days and no other antiplatelet drugs. They were evaluated
for aspirin resistance using light transmission aggregometry. Aspirin resistance was deﬁned as a
mean aggregation of >20% with 0.5 mg/ml arachidonic acid. They were followed up after six
months for cardiac death, unstable angina (UA), myocardial infarction (MI), and stroke.
Results: Prevalence of aspirin resistance was 48% in our study group. Aspirin resistance was sig-
niﬁcantly higher in patients with family history of CAD (p= 0.044), smoking (p= 0.011), history
of MI (p= 0.024), history of percutaneous coronary intervention (PCI) (p= 0.001), and concom-
itant NSAIDs intake (p= 0.047). Moreover, aspirin resistance was more common among patients
with multi-vessel CAD (p= 0.024). Aspirin-resistant patients had a signiﬁcantly higher rate of UA
(p= 0.001) and all major adverse cardiac events (MACE) (p< 0.001).
 2015 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Atherothrombosis has long been recognized as a key contribu-
tor to cardiovascular (CV) events such as myocardial infarction
(MI), unstable angina (UA), stroke, and transient ischemic
attack (TIA). Given the important role of platelets in acute
thrombus formation, antiplatelet therapies have become one
of the cornerstone treatments of these atherothrombotic
syndromes.
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Figure 1 Prevalence of aspirin resistance.
24 A. Salah et al.In 1897, Felix Hoffman ﬁrst developed acetylsalicylic acid
and registered it under the name aspirin [1]. Aspirin speciﬁcally
inhibits thromboxane (TX) A2 generation by irreversibly acet-
ylating a serine residue at position 529 of the cyclooxygenase-1
(COX-1) enzyme [2].
The Antiplatelet Trialists Collaboration has shown a 25%
reduction in strokes, MI, and CV deaths with the use of aspi-
rin. However, aspirin has been shown to have variable anti-
platelet effect in individual patients [3]. Incidence of
treatment failure occurs with any drug and aspirin is not an
exception, raising the possibility of aspirin resistance [4,5].
Aspirin resistance has been associated with adverse clinical
events, increasing both morbidity and mortality [6–11].
2. Patients and methods
The protocol of this study was reviewed and approved by the
Local Institutional Ethics Committee of Critical Care Depart-
ment, Faculty of Medicine, Cairo University, Egypt.
Additionally, written informed consent entailing all moral
and ethical consideration was obtained from all the patients
participating in the study.
2.1. Patients
Our study was conducted prospectively on patients admitted
to Critical Care Department, Faculty of Medicine, Cairo Uni-
versity, in the period from December 2009 to December 2010.
The patients included in the study had a documented history of
coronary artery disease (CAD) such as UA, MI, percutaneous
coronary intervention (PCI), and/or coronary artery bypass
graft surgery (CABG). Patients were excluded from the study
on the basis of the following reasons: (1) administration of
unfractionated heparin or low-molecular-weight heparin
LMWH in the last 24 h before platelet aggregation testing,
(2) personal history of bleeding disorders, (3) history of myelo-
proliferative disorder, (4) major surgical procedure in the last
one week, (5) platelet count less than 150 * 109/L or more than
450 * 109/L.
Based on the above criteria, 50 patients were included for
the study. Of the total selected patients, 30 (60%) patients were
male, 35 (70%) were hypertensive, 25 (50%) were diabetic, 19
(38%) were smokers, 23 (46%) were obese, 27 (54%) had a
family history of CAD, 13 (26%) had a history of MI, and nine
(18%) had a history of PCI.
All patients were maintained on aspirin (150 mg/day) for
more than seven days. No other antiplatelet therapies were
implemented for their treatment.
2.2. Platelet function testing
Three samples of whole blood were collected in 3.8% sodium
citrate (blue capped tube). The last dose of aspirin was admin-
istered within 1–24 h before sampling.
Blood samples were processed within two hrs of blood col-
lection. Whole-blood specimens were centrifuged for 10 min at
120 g to obtain platelet-rich plasma (PRP). Platelet aggrega-
tion was performed on CHRONO-LOG platelet aggregometer
(Chrono-Log Corporation, Havertown, USA) using the ago-
nist arachidonic acid (AA) at 0.5 mg/ml. The tube containing
platelet-rich plasma (PRP) was inserted in the aggregometerbetween a light source and a photocell, and then the agonist
was added. When the platelets started to aggregate, the light
transmission increased, which was directly proportional to
the percent of platelet aggregation. Aspirin resistance was
deﬁned as a mean aggregation of >20% with 0.5 mg/ml AA.
2.3. Clinical follow up and study endpoints
In-hospital and post-discharge (after six months) follow-up
data were prospectively collected. Compliance to medical
treatment including aspirin was addressed. The study end-
points were CV death, UA, MI, and non-hemorrhagic cerebro-
vascular strokes. Other clinical events in the selected patients
were assessed on the basis of phone interviews, outpatient fol-
low up, and the information gathered from the hospital re-
admission records.
2.4. Statistical analysis
Data were statistically analyzed and presented as descriptive
statistics, such as mean ± standard deviation (SD), frequen-
cies (number of cases), and percentages, etc.
Comparison of numerical variables was done using Stu-
dent’s t test for independent samples. For comparing categor-
ical data, Chi square (v2) test was performed. Exact test was
used when the expected frequency was less than 5. Accuracy
was represented using the terms sensitivity and speciﬁcity.
For our study, p values less than 0.05 were considered sta-
tistically signiﬁcant. All statistical calculations were done using
computer programs SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.
3. Results
3.1. Prevalence of aspirin resistance
On the basis of the results of light transmission aggregometry,
the patients were classiﬁed into aspirin sensitive (26/50; 52%)
and aspirin resistant (24/50; 48%) as shown in Fig. 1.
3.2. Predictors of aspirin resistance
As shown in Table 1, aspirin resistance was found to be signif-
icantly higher in patients with a family history of CAD (70.8%
vs. 38.5%, p= 0.044), smoking (58.3% vs. 19.2%, p= 0.011),
MI (41.7% vs. 11.5%, p= 0.024), PCI (37.5% vs. 0%,
p= 0.001), and concomitant non-steroidal anti-inﬂammatory
Table 1 Predictors of aspirin resistance.
Aspirin sensitive (No. = 26) Aspirin resistant (No. = 24) p Value
Mean age (years) 58.35 ± 5.05 55.54 ± 10.77 0.253
Male gender 16 14 1
Family history of CAD 10 17 0.044*
Current/recent smoking (<1Y) 5 14 0.011*
BMI >25 10 13 0.407
HTN 15 20 0.067
DM 14 11 0.777
Dyslipidemia 12 11 1
History of MI 3 10 0.024*
History of PCI 0 9 0.001*
Heart failure 4 8 0.11
PVD 0 1 0.48
History of CVS 2 1 1
Medications
NSAID intake 3 9 0.047*
Nitrates 22 20 1
ACEI/ARBs 14 11 0.777
B-blockers 23 17 0.164
Statins 9 14 0.162
Diuretics 6 7 0.867
CCBs 2 4 0.409
Presentation
Stable angina 16 11 0.256
UA 6 10
Heart failure 2 3
Angina equivalent 2 0
CAD= Coronary artery disease, BMI = body mass index, HTN= hypertension, DM= diabetes mellitus, MI = myocardial infarction,
PCI = percutaneous intervention, PVD= peripheral vascular disease, CVS = cerebrovascular strokes, NSAIDs = non steroidal anti-
inﬂammatory drugs, ACEI = angiotensin converting enzyme inhibitor, ARBs = angiotensin receptor blocker, CCBs = calcium channel
blockers.
* Statistically signiﬁcant.
Table 2 Clinical outcome among the aspirin group.
Aspirin
responders
(No. = 26)
Aspirin
resistant
(No. = 24)
p Value
Cardiac deaths 0 0
Unstable angina 0 8 (33.3%) 0.001*
NSTEMI 0 1 (4.2%) 0.48
STEMI 0 1 (4.2%) 0.48
Non hemorrhagic CVA 0 0
All MACE 0 10 (41.7%) <0.001*
NSTEMI= non ST-segment elevation myocardial infarction,
CVA= cerebrovascular accident, MACE=major adverse cardiac
events.
* Statistically signiﬁcant.
Aspirin resistance 25drug (NSAIDs) intake (37.5% vs. 11.5%, p= 0.047). More-
over, aspirin resistance was found to be more evident among
patients with multi-vessel CAD (58.3% vs. 41.7%,
p= 0.024) as shown in Fig. 2.
No statistical differences were observed for parameters like
age, gender, BMI, diabetes, hypertension, and dyslipidemia
(p> 0.05).
3.3. Study endpoints
No patients were lost to follow-up. In the aspirin sensitive
group, 26 (100%) patients were event-free, while in the aspirin
resistant group, 8 (33.3%) patients were presented with UA,
one patient (4.2%) with ST segment elevation myocardial
infarction (STEMI) and one patient (4.2%) with non-STEMI
(NSTEMI). There were neither CV deaths nor cerebrovascular
accidents (CVA) in both groups, as shown in Table 2.0 
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Figure 2 Coronary angiography result and aspirin resistance.4. Discussion
Aspirin resistance is one of the important issues in current CV
medicine. Antithrombotic Trialists’ Collaboration provided
evidence that 75–150 mg daily aspirin dosage is an effective
method for secondary CV prevention [3]. Moreover, a signiﬁ-
cant number of patients do not get any beneﬁt from aspirin
monotherapy or even aspirin and clopidogrel dual therapy
[12]. So, we initiated this study to estimate the prevalence of
aspirin resistance in patients with CAD and to evaluate its
impact on clinical outcome in our population.
26 A. Salah et al.In our study, the prevalence of aspirin resistance was noted
to be 48%. This number was going parallel to other studies.
Buchanan et al. [13] who studied 40 post-CABG patients trea-
ted with 325 mg of aspirin daily, found that approximately
42% of the patients were considered non-responders.
The Muller et al. [14] study also assessed 100 patients with
peripheral vascular disease for aspirin resistance and showed a
60% incidence of aspirin resistance.
In another study, Gum et al. [15] studied 325 patients with
stable coronary artery disease using optical platelet aggregom-
etry and showed 5.5% incidence of aspirin resistance whereas
23% were aspirin semi-responders.
Various studies using different platelet function tests
revealed estimates of aspirin resistance ranging from 5.5% to
60% [12]. This wide difference may be due to the difference
in the dosage of aspirin, the method of deﬁning resistance, type
and concentration of the agonist used in testing, baseline plate-
let reactivity, and the type of population selected in the study
(stable or unstable CAD, post CABG, post PCI, etc.).
Regarding predictors of aspirin resistance, we found that
aspirin resistance was signiﬁcantly higher in patients with a
family history of CAD, history of MI, history of PCI, and con-
comitant NSAIDs intake. Also, aspirin resistance was signiﬁ-
cantly higher in patients who were current/recent smokers.
Similar to our results, Kojuri et al. [16] prospectively stud-
ied the effect of aspirin on platelet function in 106 stable out-
patients. Six months after successful PCI, they observed that
smoking (p= 0.04) was strongly associated with aspirin
resistance.
Other studies, including Catella-Lawson et al. and Kurth
et al. [17,18], also found that aspirin resistance was signiﬁ-
cantly elevated in patients with concomitant NSAIDs intake.
NSAIDs (especially ibuprofen) may compete with aspirin
for binding to a speciﬁc serine residue on COX-1 enzyme
and can potentially interfere with the cardioprotective effect
of aspirin [19,20]. Hence, in September 2006, the Food and
Drug Administration issued a statement for the physicians to
be minded of this interaction [21].
In our study, we found no association between the female
gender and aspirin resistance (p= 1); however in the work
of Chen et al. [22] there was a signiﬁcantly higher incidence
of female subjects in the aspirin-resistant group. In another
systematic review and meta-analysis of 20 studies that included
2930 patients with CV disease, aspirin resistance was found to
be less prevalent in men than in women (p< 0.001) [23].
The same result was observed by Al-Azzam et al. [24] who
studied 418 patients taking aspirin. The data collected in their
research showed that aspirin resistance was not related to
parameters, such as glycated hemoglobin (HbA1c), low-den-
sity lipoproteins (LDL), hypertension, age, and BMI, but
was associated with the female gender (p< 0.05).
The difference between these results and the result obtained
in our study may be attributed to the limited number of
females enrolled (20 females).
In our study, aspirin resistance was found to be more preva-
lent in patients with multi-vessel CAD. However, in the study
of Hobikoglu et al. [25], there were no signiﬁcant differences
in angiographic severity and the extent of coronary artery dis-
ease between the aspirin-resistant and aspirin-sensitive patients.
Many studies demonstrated the association of adverse clin-
ical events in patients with aspirin resistance as determined by
different assays [6–8,14,22,23,26]. Our study extended theseobservations and provided further evidence on the clinical sig-
niﬁcance of aspirin resistance as aspirin non-responders had a
signiﬁcant higher rate of UA (p= 0.001) and all major adverse
cardiac events (MACE) (p< 0.001).
Our study had several potential limitations: (1) The study
population was small, so important trends may not be identi-
ﬁed because of a lack of statistical signiﬁcance. (2) The anti-
platelet effect may ﬂuctuate in patients at the same dosage,
so multiple measurements may be required to reﬂect the extent
of platelet inhibition over a long period of time. (3) The lack of
standardized timing between aspirin administration and blood
sampling which is important, because the platelet inhibitory
effect of aspirin declines through the usual 24-h interval [27].
(4) The study ﬁndings may not be extrapolated to other stud-
ies, since platelet aggregometry results obtained with different
platelet aggregation tests do not correlate particularly well [28].
5. Conclusion
Prevalence of aspirin resistance among patients included in this
study was 48%. Possible predictors of aspirin resistance
included family history of CAD, history of MI, history of
PCI, current/recent smoking, and concomitant NSAIDs
intake. Aspirin resistance was more common among patients
with multi-vessel CAD, and aspirin resistant patients had sig-
niﬁcantly higher rates of UA and MACE.
Recommendations
Larger, prospective, randomized and blinded studies are
needed to accurately estimate the prevalence of antiplatelet
resistance in our population, also possible treatment strategies
and the role of platelet aggregation test in guiding antiplatelet
therapy.Conﬂict of interest
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